
BioNTech SE (BNTX) Stock Forecast & Price Target
BioNTech SE (BNTX) Analyst Ratings
Bulls say
BioNTech is projected to have a firm value of $33 billion and a projected price objectiveof $130 per share. One of the main risks for the company is negative data for its various oncology drugs, and potential commercial risks and dilution risks. However, BioNTech has a strong lead in development with its commercialized product, and recent data has shown positive results for its oncology drugs, which could offset potential risks in the future. The company is also quickly transitioning to focus on its oncology pipeline, with a projected decline in COVID revenue over the next few years but a strong focus on advancing its oncology pipeline. The departure of the company's co-founders to start a new mRNA biotech also signals a dedicated focus on the company's oncology programs.
Bears say
BioNTech is a biotechnology company whose leadership team announced their departure to focus on a new venture, creating a ~20% decline in stock price and rattling investor confidence in the company's prospects. Clinical, regulatory, and competitive risks pose a threat to BioNTech's drug candidates, and any potential delays could significantly impact future revenue generation. The company has a diverse pipeline and potential value of $171 per common share, but with potential risks and uncertainties, the current valuation may not be justified.
This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.
BioNTech SE (BNTX) Analyst Forecast & Price Prediction
Start investing in BioNTech SE (BNTX)
Order type
Buy in
Order amount
Est. shares
0 shares